|
KMID : 0387820160230010042
|
|
Clinical Pediatric Hematology-Oncology
2016 Volume.23 No. 1 p.42 ~ p.45
|
|
|
Use of Recombinant Activated Factor VII for Pulmonary Hemorrhage in Premature Infants: A Single-Center Experience
|
|
Park Hye-Jin
Choi Eun-Jin
|
|
|
Abstract
|
|
|
Background: Pulmonary hemorrhage in prematurity is a life-threatening complication and associated with a high mortality. Recombinant activated factor VII (rFVIIa) has been reported as hemostatic treatment in sick neonates with refractory bleeding events in many studies. We evaluated the efficacy and safety of rFVIIa in prematurity with pulmo-nary hemorrhage in our institution.
Methods: From the prematurities who were treated with rFVIIa to pulmonary hemorrhage from January 2010 to December 2015, we retrospectively analyzed the results of rFVIIa.
Results: Of the 29 prematurities who were treated with rFVIIa for pulmonary hemor-rhage, fifteen were male and fourteen were female. The median gestational age was 27 1/7 weeks (range, 22 1/7-34 1/7 weeks) and median birth weight was 870 g (range, 470-2,070 g). One to eight doses of rFVIIa (median dose 115.6 μg/kg/dose) were ad-ministered, with 16 (55%) patients receiving a single dose. Hemostatic effect was ach-ieved in 21 (72.4%) cases, but 6 of 21 patients died of unrelated cause, and overall mortality was 14 of 29 (48.3%). Thrombotic adverse event was not observed in any of our patients.
Conclusion: Although the number of patients included in this study was small and the fact that this was a retrospective non-randomized control study, rFVIIa could be consid-ered as a therapeutic option for pulmonary hemorrhage in prematurity.
|
|
|
KEYWORD
|
|
|
Pulmonary hemorrhage, Prematurity, Recombinant, Activated factor VII
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|